Heron Therapeutics (HRTX) Projected to Post Quarterly Earnings on Tuesday

Heron Therapeutics (NASDAQ:HRTX) is projected to release its Q1 2025 earnings data before the market opens on Tuesday, May 6th. Analysts expect Heron Therapeutics to post earnings of ($0.02) per share and revenue of $37.08 million for the quarter. Heron Therapeutics has set its FY 2025 guidance at EPS.

Heron Therapeutics (NASDAQ:HRTX) last issued its quarterly earnings data on Thursday, February 27th. The biotechnology company reported $0.02 EPS for the quarter, beating the consensus estimate of ($0.03) by $0.05. The business had revenue of $40.78 million for the quarter, compared to analysts’ expectations of $37.37 million. On average, analysts expect Heron Therapeutics to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Heron Therapeutics Price Performance

Shares of HRTX opened at $2.33 on Tuesday. The firm has a market capitalization of $354.93 million, a PE ratio of -12.94 and a beta of 1.39. The company’s fifty day moving average price is $2.13 and its 200-day moving average price is $1.79. Heron Therapeutics has a 1-year low of $1.04 and a 1-year high of $3.93.

Analysts Set New Price Targets

A number of research firms have commented on HRTX. Needham & Company LLC reiterated a “buy” rating and issued a $4.00 price objective on shares of Heron Therapeutics in a report on Friday, April 11th. StockNews.com cut shares of Heron Therapeutics from a “buy” rating to a “hold” rating in a research report on Saturday, March 8th.

About Heron Therapeutics

Heron Therapeutics, Inc, a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.